Aridis Pharmaceuticals, Inc.
ARDS
$0.0001
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -97.88% | 1,715.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -97.88% | 1,715.80% | |||
| Cost of Revenue | -96.25% | -15.60% | |||
| Gross Profit | -98.38% | 436.68% | |||
| SG&A Expenses | -15.19% | -27.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -78.49% | -18.61% | |||
| Operating Income | -106.36% | 318.25% | |||
| Income Before Tax | -100.68% | 278.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -100.68% | 278.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -100.68% | 278.17% | |||
| EBIT | -106.36% | 318.25% | |||
| EBITDA | -105.90% | 322.34% | |||
| EPS Basic | -100.65% | 250.11% | |||
| Normalized Basic EPS | -105.94% | 285.89% | |||
| EPS Diluted | -100.67% | 247.26% | |||
| Normalized Diluted EPS | -106.03% | 283.31% | |||
| Average Basic Shares Outstanding | 3.68% | 18.69% | |||
| Average Diluted Shares Outstanding | 2.26% | 20.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||